Ac­er, Re­lief win FDA ap­proval for rare meta­bol­ic dis­ease af­ter clear­ing in­spec­tion hur­dles

Ac­er Ther­a­peu­tics and its Swiss part­ner Re­lief Ther­a­peu­tics cel­e­brat­ed an FDA ap­proval on Tues­day for Ol­pru­va, an oral drug for urea cy­cle dis­or­ders (UCDs). …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER